florbetaben F-18 (neuraceq) Report issue

Small molecule Imaging Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Florbetaben F18 is a18F-labeled stilbene derivative used as a tracer for PET imaging of beta-amyloid deposits in the human brain. The F 18 isotope produces a positron signal that is detected by a PET scanner. 3H-florbetaben in vitro binding experiments reveal two binding sites (Kd of 16 nM and 135 nM) in frontal cortex homogenates from patients with AD. Binding of florbetaben F18 to beta-amyloid plaques in post-mortem brain sections from patients with AD using autoradiography correlates with both immunohistochemical and Bielschowsky silver stains. Florbetaben F 18 does not bind to tau or alpha-synuclein in tissue from patients with AD. Neither Neuraceq nor non-radioactive florbetaben F 19 bind to AT8 positive tau deposits in brain tissue from patients with frontotemporal dementia (FTD), using autoradiography and immunohistochemistry, respectively.   NCATS

Chemistry

  • SMILES: CNc1ccc(\C=C\c2ccc(OCCOCCOCCF)cc2)cc1
  • InChIKey: NCWZOASIUQVOFA-NSCUHMNNSA-N
  • Mol. Mass: 359.44
  • ALogP: 4.28
  • ChEMBL Molecules:
    florbetaben  
    florbetaben f18  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Imaging: 18-fluorine
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

18f-bay94-9172 | [18f]florbetaben | 18f-florbetaben | 4-(n-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene | bay 94-9172 | bay-949172 | bay94 9172 | bay94-9172 | florbetaben | florbetaben (18f) | florbetaben f18 | florbetaben f-18 | florbetaben f18 injection | neuraceq | unii-tla7312toi

Organizations (16)

Research & Development (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Alzheimer Disease (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Alzheimer Disease (Phase 4)

Amyloid beta-Peptides (Phase 2)

Amyloidosis (Phase 3)

Cognition Disorders (Phase 2)

Down Syndrome (Phase 2)

Immunoglobulin Light-chain Amyloidosis (Phase 3)

Physiology (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial Organizations: 16

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue